Grants per year
Personal profile
Training Experience
| 2003 | Residency, Royal College of Physicians, Ireland |
| 2009 | Fellowship, University of Texas Health Science Center, San Antonio |
| 2009 | Fellowship, Royal College of Physicians, Ireland |
Education/Academic qualification
PhD, National University of Ireland
… → 2009
MBBChBAO, National University of Ireland
… → 2000
Fingerprint Dive into the research topics where Devalingam Mahalingam is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 13 Similar Profiles
Neoplasms
Medicine & Life Sciences
Apoptosis
Medicine & Life Sciences
gemcitabine
Medicine & Life Sciences
Therapeutics
Medicine & Life Sciences
Prostatic Neoplasms
Medicine & Life Sciences
TNF-Related Apoptosis-Inducing Ligand Receptors
Medicine & Life Sciences
Colorectal Neoplasms
Medicine & Life Sciences
Safety
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Grants 2017 2022
- 10 Active
Prot #19774: A multicenter Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of the combination of rogaratinib and copanlisib in patients with FGFR-positive, local
Bayer HealthCare Pharmaceuticals, Inc.
10/18/18 → 5/19/21
Project: Research project
Research Output 2008 2019
1
Citation
(Scopus)
A phase II, multicenter, single-arm study of mipsagargin (G-202) as a second-line therapy following sorafenib for adult patients with progressive advanced hepatocellular carcinoma
Mahalingam, D., Peguero, J., Cen, P., Arora, S. P., Sarantopoulos, J., Rowe, J., Allgood, V., Tubb, B. & Campos, L., Jun 1 2019, In : Cancers. 11, 6, 833.Research output: Contribution to journal › Article
Open Access
Hepatocellular Carcinoma
Disease-Free Survival
Disease Progression
Neoplasms
Magnetic Resonance Imaging
Current state of liver-directed therapies and combinatory approaches with systemic therapy in hepatocellular carcinoma (HCC)
Viveiros, P., Riaz, A., Lewandowski, R. J. & Mahalingam, D., Aug 1 2019, In : Cancers. 11, 8, 1085.Research output: Contribution to journal › Review article
Open Access
Hepatocellular Carcinoma
Liver
Therapeutics
Protein-Tyrosine Kinases
Immunotherapy
Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up
Rosenberg, A. J., Rademaker, A. W., Hochster, H. S., Ryan, T., Hensing, T., Shankaran, V., Baddi, L., Mahalingam, D., Mulcahy, M. F. & Benson, A. B., Jan 1 2019, In : Oncologist. 24, 8, p. 1039-e642Research output: Contribution to journal › Article
oxaliplatin
docetaxel
Esophagogastric Junction
Fluorouracil
Stomach
Heightened JNK activation and reduced XIAP levels promote TRAIL and sunitinib-mediated apoptosis in colon cancer models
Mahalingam, D., Carew, J. S., Espitia, C. M., Cool, R. H., Giles, F. J., De Jong, S. & Nawrocki, S. T., Jul 1 2019, In : Cancers. 11, 7, 895.Research output: Contribution to journal › Article
Open Access
X-Linked Inhibitor of Apoptosis Protein
Colonic Neoplasms
Phosphotransferases
Apoptosis
Neoplasms
Phase 1 open-label, multicenter study of first-in-class RORγ agonist LYC-55716 (Cintirorgon): Safety, tolerability, and preliminary evidence of antitumor activity
Mahalingam, D., Wang, J. S., Hamilton, E. P., Sarantopoulos, J., Nemunaitis, J., Weems, G., Carter, L., Hu, X., Schreeder, M. & Wilkins, H. J., Jun 15 2019, In : Clinical Cancer Research. 25, 12, p. 3508-3516 9 p.Research output: Contribution to journal › Article
Open Access
Multicenter Studies
Safety
Pharmacokinetics
Anemia
Hypophosphatemia